Get the Stockscreener App
1.71
3.93%
-0.07
After Hours:
1.73
0.02
+1.17%
Palisade Bio Inc stock is traded at $1.71, with a volume of 2.18M.
It is down -3.93% in the last 24 hours and down -10.94% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$1.78
Open:
$1.78
24h Volume:
2.18M
Relative Volume:
0.60
Market Cap:
$297.16M
Revenue:
$250.00K
Net Income/Loss:
$-24.15M
P/E Ratio:
-1.6047
EPS:
-1.0656
Net Cash Flow:
$-12.40M
1W Performance:
-1.72%
1M Performance:
-10.94%
6M Performance:
-11.86%
1Y Performance:
+147.83%
1-Day Range:
$1.69
$1.81
1-Week Range:
$1.64
$1.81
52-Week Range:
$0.53
$2.855
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.71 | 297.16M | 250.00K | -24.15M | -12.40M | -1.0656 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-26-26 | Initiated | H.C. Wainwright | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
Palisade Bio (PALI) director Jordan Michael Zwick files baseline Form 3 - Stock Titan
Palisade Bio (PALI) director gets 592,300 RSU grant and 20,200 RSUs vest - Stock Titan
Palisade Bio (PALI) director reports major RSU grant and new share holdings - Stock Titan
Palisade Bio (PALI) director Emil Chuang reports new RSU awards - Stock Titan
Palisade Bio (PALI) Holds Steady Near Key Support After Modest GainTriple Top - lwvtexas.org
Palisade Bio, Inc. Approves Amendments to Equity Incentive and Employee Stock Purchase Plans at 2026 Annual Meeting – Minichart - Minichart
Palisade Bio Shareholders Approve Charter Amendments, Governance Matters - TipRanks
Palisade Bio (PALI) raises authorized shares to 450M and refreshes equity plans - Stock Titan
Palisade Bio adds two directors with biotech expertise - Investing.com
Palisade Bio adds two directors with biotech expertise By Investing.com - Investing.com Canada
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors - GlobeNewswire
PALI Q1 2026 Earnings: Net Loss Wider Than Estimates as Pre-Revenue Biotech Advances PipelineSpecial Dividend Alert - newsline.com
Palisade Bio, Inc. to Present on PDE4 Inhibitor Prodrug Approach for Fibrostenotic Crohn's Disease at NYAS Symposium - Quiver Quantitative
Experimental pill targets fibrostenotic Crohn’s, a form with no approved drugs - Stock Titan
B. Riley Securities Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Palisade Bio (PALI) Gets a Buy from B. Riley Securities - The Globe and Mail
PALI Technical Analysis | Trend, Signals & Chart Patterns | PALISADE BIO INC (NASDAQ:PALI) - ChartMill
PALI Q1 2026 Earnings: Deeper Loss Than Expected as Pre-Revenue Biotech Faces Market SkepticismProfit Cycle Analysis - newsline.com
[SCHEDULE 13G] PALISADE BIO, INC. Passive Investment Disclosure (>5%) - Stock Titan
Palisade Bio to present at Jefferies Healthcare... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Palisade Bio to Participate in the Jefferies Global Healthcare Conference - Weekly Voice
Palisade Bio to present once-daily PDE4 prodrugs at NYC event - Stock Titan
Verra Mobility, Zscaler, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Palisade Bio Inc. (PALI) Edges Higher on Modest Volume, Testing Resistance LevelsPassive Flow - The Legal Advocate
Palisade Bio (PALI) Edges Higher as Shares Test Key Resistance ZoneFund Manager Survey - newsline.com
PALI Q1 2026 Earnings: EPS Misses Estimates as Palisade Bio Advances Pipeline EffortsGuidance Downgrade Alert - Newser
PALI Should I Buy - Intellectia AI
[EFFECT] PALISADE BIO, INC. SEC Filing - Stock Titan
Palisade Bio, Inc.Common Stock (NQ: PALI - FinancialContent
Palisade Bio Records Q1 Earnings and Advances Clinical Pipeline - HarianBasis.co
Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M - Insider Monkey
Number of shareholders of Palisade Bio, Inc. – MUN:7NS0 - TradingView
10 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
RA Capital and partners disclose 9.99% stake in Palisade Bio (PALI) via warrants and shares - Stock Titan
[SCHEDULE 13G/A] PALISADE BIO, INC. Amended Passive Investment Disclosure - Stock Titan
Commodore Capital reports 12.37M-share stake in Palisade Bio (PALI) - Stock Titan
Perceptive Advisors (NASDAQ: PALI) reports a 7.9% collective stake in Palisade Bio - Stock Titan
Ameriprise/Columbia disclose 8.71M-share stake in Palisade Bio (NASDAQ: PALI) - Stock Titan
We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI) - The Globe and Mail
Palisade Bio Incmay offer and sell up to $300 million of securitiesSEC filing - marketscreener.com
Palisade Bio (NASDAQ: PALI) files $300M shelf to offer securities - Stock Titan
Palisade Bio Q1 net loss widens on higher R&D costs - TradingView
Palisade Bio (PALI) ramps PALI-2108 trials with $132.6M cash runway - Stock Titan
BRIEF-Palisade Bio Q1 EPS USD -0.05 - TradingView
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 - GlobeNewswire
Palisade Bio (NASDAQ: PALI) boosts R&D spend to advance PALI-2108 - Stock Titan
Palisade Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
Palisade Bio Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Palisade Bio (PALI) price target decreased by 12.09% to 10.20 - MSN
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Palisade Bio Inc Stock (PALI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Finley John David | CEO, CFO |
Feb 12 '26 |
Sale |
1.75 |
3,896 |
6,818 |
27,353 |
| Williams Donald Allen | Director |
Jan 16 '26 |
Buy |
1.67 |
5,000 |
8,356 |
10,728 |
| Williams Donald Allen | Director |
Jan 09 '26 |
Buy |
1.88 |
5,000 |
9,400 |
5,728 |
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):